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Background: Tumor buds are associated with lympho-vascular invasion and lymph node metastases leading to
the assumption that they are involved in the early metastatic process. Hence, it would be important to know if
tumor buds can be targeted with the most widely used targeted therapies in breast cancer (BC) and if changes in
hormone and Her2 status occur. The aim of this study was to answer these questions by determining whether
hormone receptor (HR) and Her2 status are expressed in the tumor buds of a large cohort of BCs.
Design: We constructed a tumor bud next-generation tissue microarray (ngTMA) consisting of n=199 BCs of
non-special type. Generally, two 1mm punches were taken from the tumor bud areas in the periphery (PTB) and
within the tumor center (ITB). HR and Her2 status was assessed using immunohistochemistry and ﬂuorescence
in situ hybridization, respectively. HR status was positive if ≥1% of tumor bud cells were positive. Her2 status
was considered positive if bud cells showed strong complete membranous Her2 over-expression or Her2 am-
pliﬁcation.
Results: Most tumor buds were positive for estrogen (ER) (PTB: 86%; ITB: 88.3) and progesterone receptor (PgR)
(PTB: 72%; ITB: 72.8%) and Her2 was positive in: PTB 11.5% and ITB 11%. A diﬀerence between the main
tumor mass and tumor buds (PTB and ITB) was seen for PgR in 3.5% of cases (n=7). No diﬀerences were seen
for ER and Her2 between tumor buds and main tumor mass.
Conclusion: Most tumor buds (96.5%) share the same HR and Her2 expression proﬁle of the main tumor mass,
implying that tumor buds relay on the same pathways as the main tumor mass and might be equally responsive
to targeted therapies.
1. Introduction
Tumor buds are small cell clusters or single tumors cells, detaching
from the main tumor mass. This phenomenon can be seen within the
tumor (intra-tumoral budding), or at the tumor periphery (peripheral
tumor budding) [22,27,19]. Tumor budding is best characterized in
colon cancer [6,19,31] but it is increasingly recognized and described
in other tumor types such as e.g. breast, pancreatic-, esophagus-, larynx-
and other cancers [16–18,22–25,27]. In breast cancer (BC) and other
tumor types, high numbers of tumor buds are associated with lympho-
vascular invasion (LVI) and/or lymph node metastasis [16,18,22,27].
Additionally, high numbers of tumor buds are associated with shorter
overall and cancer-speciﬁc survival in BC [8,18] and this has been
described in other tumor types as well [6,15]. The association of
vascular invasion and tumor budding led to the assumption that tumor
buds are involved in the early metastatic process by undergoing epi-
thelial-mesenchymal transition (EMT) [8,19]. It is well-known that
tumor cells undergoing EMT are more invasive and prone to metasta-
size that can lead to worse overall survival in cancer patients [1,10,23].
Inhibiting tumor cells involved in the early metastatic process
would be of great clinical value since metastatic disease remains the
major cause of cancer deaths with around 30% of BC patients devel-
oping metastasis [4,20]. This indicates that a better understanding of
the metastatic process is needed in order to develop novel targeted
approaches for highly aggressive and invasive cancer to improve pa-
tient outcomes. If tumor buds are involved in the early metastatic
process, then it would be advantageous to determine whether and how
they can be uniquely targeted. Tumor buds are known to have
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characteristics of EMT and in breast cancer, estrogen and Her2 over-
expression was shown to be involved in EMT [11,13]. However, little is
known regarding the expression of markers commonly targeted in
breast cancer such as the estrogen and progesterone receptors and Her2
status in tumor buds.
Hence, the aim of this study was to examine the immunophenotypic
proﬁle of tumor buds to determine if they are targetable with the most
widely used targeted therapies in BC, such as anti-hormonal and anti-
Her2 therapy. In the current study, we report the estrogen, proges-
terone and Her2 receptor status of a large number of tumor buds in BC
of non-special type (NST) using a next-generation tissue microarray
(ngTMA).
2. Material and methods
Patients: We selected 199 NST BCs out of our previously described
cohort of 356 therapy naïve, unilateral BCs diagnosed in female pa-
tients that underwent surgery between 2005 and 2011 at the Inselspital
Bern, Switzerland [7]. T category was available for all BCs and N ca-
tegory was available for n= 181 (91%). Tumor grading, estrogen-,
progesterone-, and Her2 receptor status (ER, PgR and Her2) and the
molecular subtypes according to the St. Gallen 2013 criteria from the
main tumor mass was available from our previous studies [7,22]. The
median age at diagnosis was 64 years (range: 33–98 years) and clinical
information regarding chemotherapy was available for 100 (50.2%)
cases; for anti-hormone therapy for n= 102 (51.3%), for anti-her2
therapy in n=95 (47.7%); and for radiation therapy for n=140
(70.9%) cases. The clinic-pathological characteristics are shown in
Table 1. The study was approved by the ethical commission of the
University of Bern (Registration 200/2014).
Next-generation tissue microarray (ngTMA) of tumor buds: The
ngTMA was constructed as previously described (3DHistech, Budapest,
Hungary) [33]. In brief, pathologists reviewed breast cancer cases using
H&E slides [7]. The decision, what block should be use for the per-
ipheral and intra-tumoral bud ngTMA was made by one pathologist
(CT). The H&E slides where then scanned and uploaded to the digital
platform to perform annotation on the computer screen. Whenever
feasible, two areas from peripheral and central tumor buds were pun-
ched. We successfully made two 1mm punches in 199 and 193 of PTB
and ITB cases, respectively.
Deﬁnition and assessment of tumor buds: We used our previous
deﬁnition of tumor buds: One isolated tumor cell or a small tumor cell
clusters of up to 5 tumor cells [22]. The slides of the tumor bud ngTMA
were stained with ER, PgR and Her2 using the same antibodies and
conditions as in our previous study [22]. Brieﬂy, any nuclear ER and
PgR staining, regardless of intensity, was considered as positive. The
cases were then dichotomized into negative and positive cases ac-
cording to the cut-oﬀ of≥1% [9]. Her2 status was evaluated according
to ASCO/CAP guidelines 2013 [30]. ER and PgR positive tumor cells
were estimated in the tumor buds and a positive rate of ≥1% positive
tumor cells was regarded as a positive hormone (HR) status. For HR
status any intensity of nuclear staining was regarded as positive and the
cases were dichotomized into negative and positive cases according to
the cut-oﬀ of≥1%. A strong, complete membranous staining for Her2,
or a Her2 ampliﬁcation was considered Her2 positive. Diﬀerence in ER
and PgR status was deﬁned according to the dichotomized result ob-
tained for the main tumor and the tumor buds or according to the de-
ﬁned positive expression of Her2 status.
Statistics: We used the Pearson Chi-Square test to calculate sig-
niﬁcant correlations between categorical variables. A p-value of< 0.05
was considered statistically signiﬁcant. Analyses were carried out using
the IBM SPSS Statistics 22.0 (IBM, Armonk, NY, USA).
3. Results
3.1. Peripheral tumor buds (PTB)
Informative ER, PgR and Her2 results were available for 172
(86.9%), 168 (84.8%), and 156 (78.8%) cases. ER status was positive in
148 (86%) cases. Her2 status was positive in 18 (11.5%). PgR was
positive in 121 (72%). No diﬀerence in ER or Her2 status was seen
between main tumor mass and tumor buds. However there was a dif-
ference in receptor status between main tumor mass and buds for PgR
in 6 (3.6%; 6/168) cases. All cases showed a positive PgR status in the
main tumor mass but were negative in PTBs. Comparing the diﬀerences
of PgR status with the molecular subtypes of the main tumor mass
diﬀerences in 2 (2%) of luminal A, and 4 luminal B (Her2-negative)
(10%) were observed. No diﬀerences in other molecular subtypes were
seen.
Table 1
Patient characteristics of the whole cohort (n= 199).
Feature Frequency n (%)
Age at diagnosis (years) Median (min, max) 64 (33, 98)
Tumor size (centimeter) Mean (min, max) 2.4 (0.6, 8.4)
ER positive 165 (82.9)
negative 34 (17.1)
PgR positive 142 (71.4)
negative 57 (28.6)
Her2 negative 177 (88.9)
positive 21 (10.6)
No data 1 (0.5)
Nottingham Grad G1 21 (10.6)
G2 97 (48.7)
G3 81 (40.7)
LVI Yes 82 (41.2)
No 104 (52.3)
No data 13 (6.5)
V1 Yes 21 (10.6)
No 161 (80.9)
No data 17 (8.5)
Pn1 Yes 26 (13.1)
No 148 (74.3)
No data 25 (12.6)
pT T1 92 (46.2)
T2 93 (46.8)
T3 7 (3.5)
T4 7 (3.5)
pN N0 84 (42.3)
N1mi 11 (5.5)
N1 60 (30.2)
N2 17 (8.5)
N3 9 (4.5)
No data 18 (9.0)
Recurrence Yes 12 (6.0)
No data 187 (94)
Molecular subtypes (St. Gallen
2013)
Luminal A 106 (53.3)
Luminal B (her2
negative)
44 (22.1)
Luminal B (her2
positive)
14 (7.0)
Her2 non-luminal 7 (3.5)
Triple negative 26 (13.1)
no data 2 (1.0)
Anti-hormonal therapy Yes 42 (21.1)
No 60 (30.2)
No data 97 (48.7)
Chemotherapy Yes 37 (18.6)
No 63 (31.7)
No data 99 (49.7)
Anti-her2 therapy Yes 5 (2.5)
No 90 (45.2)
No data 104 (52.3)
Radiation therapy Yes 100 (50.3)
No 40 (20.1)
no data 59 (29.6)
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3.2. Intra-tumoral buds (ITB)
Informative ER, PgR and Her2 results were available for 179
(92.7%), 169 (87.6%), and 173 (89.6%) cases. As for PTB, no diﬀerence
in ER or Her2 status was seen between main tumor mass and tumor
buds. ER status was positive in 158 (88.3%) cases. PgR status was po-
sitive in 123 (72.8%) cases, and Her2 status was positive in 19 (11%)
cases. A diﬀerence in receptor status between main tumor mass and
buds was seen again only for PgR in 2 (1.2%: 2/169) cases. The two
cases were positive for PgR status in the main tumor mass but negative
in ITB. Comparing the diﬀerences of PgR status with the molecular
subtypes of the main tumor mass diﬀerences in 1 luminal B (Her2-ne-
gative) (2%) and in 1 luminal B (Her2-positive) (7%) was seen. No
diﬀerences in other molecular subtypes were seen. The summary of
cases that diﬀerent PgR status is given in Table 2. Examples of positive
HR and Her2 status and diﬀerence of PgR status are shown in Fig. 1.
3.3. Signiﬁcant associations of HR status and PTB
ER positive PTB were signiﬁcantly (p < 0.05) associated with the
following characteristics of the main tumor: ER positivity, PgR posi-
tivity low proliferation (< 20%), low tumor grade, and luminal mole-
cular subtypes.
PgR positive PTB were signiﬁcantly (p < 0.05) associated with the
following characteristics of the main tumor: ER positivity, PgR posi-
tivity low proliferation (< 20%), low tumor grade, vascular invasion
(V1), and luminal molecular subtypes.
3.4. Signiﬁcant associations of HR status and ITB
ER positive ITB were signiﬁcantly (p < 0.05) associated with the
following characteristics of the main tumor: ER positivity, PgR posi-
tivity, negative Her2 status, low proliferation (< 20%), low tumor
grade tumors, and luminal molecular subtypes.
PgR positive PTB were signiﬁcantly (p < 0.05) associated with the
following characteristics of the main tumor: ER positivity, PgR posi-
tivity, low proliferation (< 20%), low tumor grade, vascular invasion
(V1), and luminal molecular subtypes.
4. Discussion
Targeting BC tumor buds, a tumor cell population regarded as
highly migratory and invasive [8] could be crucial in interfering with
tumor progression. Tumor buds were shown to have an EMT phenotype
e.g. with vimentin, or ß-catenin expression and loss of e-cadherin
[6,18]. In breast cancer (BC), it was reported that ER and Her2 play a
role in EMT. In experiments with BC cell lines, it was shown that ER
disrupts tight-junctions [13] and Her2 overexpression in breast
epithelial cell lines with stem cell properties leading to EMT by loss of
epithelial markers [11,13]. According to this data, we hypothesized
that hormone receptor (HR) and Her2 status might change in tumor
buds, which may be important in targeting tumor buds with anti-hor-
monal or anti-Her2 therapies. However, hormone and Her2 status are
highly conserved, and ITB and PTB shared in the majority of cases the
HR and Her2 status of the main tumor mass. These results indicate that
BC tumor buds seem to rely on the same pathways as the cohesive
tumor cells. This assumption, that main tumor mass and tumor buds can
share the same proﬁles, is supported by a recent observation made in
colon cancer, which revealed that the driver mutations in the main
tumor mass and in tumor buds remained unchanged [3]. According to
these results, we argue that tumor buds are equally responsive to anti-
hormonal and anti-Her2 therapy as the main tumor mass.
We observed only diﬀerent results for PgR status, whereas ER and
Her2 showed consistent expression between tumor buds and the main
tumor mass. Diﬀerences in PgR receptor could have diﬀerent reasons.
HR status can be heterogeneous within the tumor and all BCs with
diﬀerent results were heterogeneous for PgR expression and positivity
might not have been captured in the tumor bud ngTMA. Although
working with TMAs has been regarded as a weakness, TMAs are an
excellent high throughput screening tool for protein expression [2,26],
and ngTMAs have been shown to be suitable for characterizing tumor
buds [33]. However, an underlying biological background of PgR status
change cannot be excluded. In vivo experiments in breast cancer cell
lines showed that progesterone can lead to inhibition of EMT relevant
proteins such as e.g. e-cadherin due to binding with progesterone re-
ceptor alpha [34] and in endometrial cancer, it was suggested that the
Wnt/beta-catenin pathway is inhibited by progesterone in the presence
of progesterone receptor [29]. Hence, loss of PgR would favor EMT and
EMT is reported to be a characteristic of tumor buds [18,19]. Loss of
PgR expression was reported to be an independent factor for low sur-
vival rates in breast cancer [21]. A large cohort with long-term follow-
up and survival data is needed to determine if loss of PgR expression in
tumor buds represents a change in tumor biology towards a more ag-
gressive tumor phenotype.
We did not identify any diﬀerence, in particular, no change to po-
sitive hormone or Her2 status in tumor buds in triple negative BCs
(TNBC). ER, PgR and Her2, up-or down regulation, might facilitate EMT
and tumor budding but other pathways must play a role. TNBC can be
positive for many EMT markers such as e.g. vimentin [5,12] and vi-
mentin was shown to be expressed in tumor buds of BCs [18]. Hence, to
elucidate underlying mechanisms of tumor budding in BC and BC
subtypes, other pathways and markers need to be considered besides
HR and Her2. Other factors such as processes within the tumor mi-
croenvironment should be included in this consideration. Several stu-
dies showed that the tumor stroma might play an important role in
tumor budding formation and inﬂammatory cells can be associated
Table 2
Breast cancers with diﬀerences of PgR expression.
Color code: red= postive, green=no expression. (For interpretation of the references to colour in this Table note, the reader is referred to the web version of this article.)
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with tumor buds [8,14,17,28,32], indicating that the complex phe-
nomenon of tumor budding may involve all tumor compartments. At
this point, we would argue that tumor buds are most eﬃciently targeted
through their immuno proﬁle. However, in the future, stroma and/or
immune cell modulators may prove to be equally eﬃcient.
In conclusion, for the ﬁrst time, we identiﬁed that tumor buds
generally reﬂect the targetable immuno proﬁle of the main tumor mass.
Therefore, we assume that tumor buds are equally responsive to anti-
hormonal and anti-Her2 therapies. Diﬀerent PgR status can occur in
tumor buds but its signiﬁcance is unclear and needs further
investigation.
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